Business Wire

CQN-THE-GENEVA-ASSOC.

6.3.2017 16:45:15 CET | Business Wire | Press release

Share
CORRECTING and REPLACING: The Geneva Association: How Will Risk Modelling Shape the Future of Risk Transfer? Global Experts Lead the Way

First paragraph, second sentence of release, the date should be 9th March 2017 instead of 8th March 2017.

The corrected release reads:

THE GENEVA ASSOCIATION: HOW WILL RISK MODELLING SHAPE THE FUTURE OF RISK TRANSFER? GLOBAL EXPERTS LEAD THE WAY

Leading think tank of the international insurance industry, The Geneva Association, welcomes top international experts to discuss and explore the issue – “How Will Risk Modelling Shape the Future of Risk Transfer?” This scientific seminar is co-organised with the SCOR Foundation and hosted at the SCOR Paris headquarters on 9th March 2017. It will inform a ground-breaking research report by The Geneva Association’s Extreme Events and Climate Risk Research Programme, publishing in June 2017.

The last three and a half decades have witnessed a general trend of rising economic losses associated with extreme events. This is due to multiple factors, including increased concentration of people and assets in exposed areas such as coastal regions, poor development planning and related practices, highly sophisticated but vulnerable global production processes and the increasing severity and frequency of extreme weather-related events linked to a changing climate.

Risk analysis is the foundation for informed decision-making, increasing the understanding of the characteristics of risk, supporting risk pricing, and evaluating cost–benefits of various risk management strategies. In the mid-1980s and early 1990s, a number of major catastrophes in North America and Europe led to unprecedented high losses, resulting in insolvencies and/or bankruptcies in the insurance sector, and pointing to the need for a more rigorous and quantifiable approach to assessing and underwriting risks.

The development and utilization of catastrophe risk models (cat models) over the last 25 years has revolutionized the (re)insurance industry’s approach to pricing, underwriting and managing their complex risk portfolios. Beyond the insurance sector, the international development community has also adopted these models to help governments better understand risk and make risk-based decisions, helping improve disaster and climate risk management decisions.

The seminar brings together leading international experts from the (re)insurance industry, risk modelling community, international organizations, international donors, governments and the scientific community to share experiences and explore opportunities for strengthened cooperation and partnerships. The programme will examine the following critical issues:

(i) Enhancing current cat models – building on lessons learned from their development and utilization over the last 25 years;

(ii) Finding effective pathways to expand risk information and cat risk modelling tools to support public-sector decisions; and,

(iii) Harnessing the latest scientific and technological developments for a new generation of forward-looking risk models.

Dr. Maryam Golnaraghi, Director of the Extreme Events and Climate Risks Research Programme at The Geneva Association, said: “As one of its top priorities, The Geneva Association is convening a diverse group of leading experts in the industry, cat modelling, and various areas of science and technology to explore how risk modelling can shape the future of risk transfer around the world. Specifically, we are not only exploring opportunities to enhance current cat modelling approaches, but also opportunities for harnessing scientific and technological advancements in areas such as environmental surveillance, climate monitoring and forecasting, engineering, big data, and artificial intelligence for development of the new generation of systems-based risk models that can innovate risk transfer.”

Anna Maria D’Hulster, Secretary General of the Geneva Association said, “The insurance industry has deep risk knowledge and is working at the forefront of risk assessment, risk pricing and risk transfer. Public-private partnerships could be instrumental in helping the public sector in developing risk-informed preventive measures and risk transfer programmes that help government, businesses and individuals with managing their risks.”

ENDS

Notes to Editors

The Geneva Association is the leading international insurance think tank for strategically important insurance and risk management issues. It is a unique platform for dialogue between leaders of the insurance industry and key decision-makers at the international and national levels to evidence the important social and economic role of the insurance industry.

The Geneva Association identifies fundamental trends and strategic issues where insurance plays a substantial role or which influence the insurance sector. Through the development of research programmes, regular publications and the organisation of international meetings, The Geneva Association serves as a catalyst for progress in the understanding of risk and insurance matters and acts as an information creator and disseminator.

The Geneva Association membership comprises a statutory maximum of 90 chief executive officers (CEOs) from the world’s top insurance and reinsurance companies. It organises international expert networks and manages discussion platforms for senior insurance executives and specialists as well as policy-makers, regulators and multilateral organisations.

Established in 1973, The Geneva Association, officially the “International Association for the Study of Insurance Economics”, is based in Zurich, Switzerland and is a non-profit organisation funded by its membership.

www.genevaassociation.org

Contact:

The Geneva Association
Isabel Barratt
Communications Manager
+41 44 200 49 96
isabel_barratt@genevaassociation.org

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye